Newsletter: Q2 2012
Company News
MicroConstants in Lab Manager Magazine
David Beyerlein, our Vice President of Global Operations, was interviewed by Lab Manager Magazine for their March issue. Read the article to get our perspective on running a bioanalytical CRO, including our inventory management and maintenance procedures, communication policies, and some of the challenges we have faced.
Read the article.
Case Study: ELF Sample Analysis
Our latest case study details how we helped advance our client’s clinical trial by customizing a commercially available plate-based assay to increase its sensitivity. This improvement allowed us to accurately determine drug concentration in the epithelial lining fluid (ELF) samples collected during their study.
Read the case study.
Poster Presentations
AAPS National Biotechnology Conference
We will have two poster presentations on immunogenicity and toxicokinetics at the AAPS Conference in San Diego May 21 - 22, 2012. Both posters are available on our website using the links below.
- Toxicokinetics and Immunogenicity of CBX129801, a Pegylated C-Peptide for Type 1 Diabetes Replacement Therapy, in Sprague Dawley Rats (PDF)
- Embryo-Fetal Developmental Toxicokinetic Study of CBX129801, a Bio-active C-peptide for Potential Replacement Therapy in Type 1 Diabetic Nephropathy, in Rats and Rabbits After Subcutaneous Injections (PDF)
ASMS Conference on Mass Spectrometry and Allied Topics
One of our research scientists will be presenting a poster at the ASMS Conference in Vancouver, Canada May 21 - 24, 2012. Use the link below to view the poster on our website.
MicroConstants China
New Laboratory in Beijing
MicroConstants China has relocated their laboratory to a new 8,000 square foot facility in the Huilongsen International Science & Technology Park, a premier life science park located in the Beijing Development Area (eTown). The Park occupies approximately 165,000 square feet of land, has more than 300,000 square feet of total building space, and is less than one hour away from the Beijing Capital Airport.
Previously, MicroConstants China had occupied two separate facilities in Beijing. With this move, they are able to consolidate their clinical trial management and bioanalysis operations into one location to better serve their customers. The new space features a bioanalytical laboratory, mass spectrometry laboratory, sample preparation room, freezer room, reference standards room, and archive storage space. The facility is equipped with enhanced security features including video surveillance, badge controlled access, and a fire alarm and sprinkler system.
After more than a month of intense testing and qualification of all equipment, MicroConstants China is ready to perform GLP-compliant bioanalysis at the new facility. The Netherlands GLP Compliance Monitoring Programme, who issued MicroConstants China an Endorsement of GLP Compliance last year, has scheduled an on-site visit in June to inspect the new facility for GLP compliance.
Service Spotlight
Immunoassays & Bioassays
Our Immunology Department develops and validates highly sensitive and specific immunoassays and bioassays to quantify peptide or protein drugs in various types of formulations and biological matrices. Below is a list of assays we can perform to help advance your preclinical and clinical drug development studies:
- Custom ELISA method development & validation
- ELISA kit validation
- ELISA GLP method transfer
- Immunogenicity testing
- Neutralization assays
- Enzymatic activity assays
- Biomarker assays
- Cell-based assays
Contact us for more information, or to request a quote.
<< Previous Issue | Back to Newsletters | Next Issue >>
